- Home
- CAC vs ATXS Comparison
CAC vs ATXS Comparison
Compare CAC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAC | ATXS |
|---|---|---|
| Founded | 1875 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.5M | 722.1M |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CAC | ATXS |
|---|---|---|
| Price | $41.22 | $12.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 6 |
| Target Price | ★ $47.33 | $24.33 |
| AVG Volume (30 Days) | 61.7K | ★ 992.4K |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | ★ 9.13 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $215,172,000.00 | $706,000.00 |
| Revenue This Year | $44.50 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | $11.80 | ★ N/A |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $34.53 | $3.56 |
| 52 Week High | $47.66 | $12.72 |
Technical Indicators
Market Signals| Indicator | CAC | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 67.69 | 70.17 |
| Support Level | $40.18 | $12.55 |
| Resistance Level | $41.60 | $12.69 |
| Average True Range (ATR) | 1.08 | 0.19 |
| MACD | 0.27 | -0.09 |
| Stochastic Oscillator | 100.00 | 94.96 |
Price Performance
Historical ComparisonAbout CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.